The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Psychotropic medicine consumption in 65 countries and regions, 2008-19: A longitudinal study
Open accessAbstract
Background The WHO Comprehensive Mental Health Action Plan 2013-2030 encourages routine collection and reporting of a set of essential mental health indicators, including the availability of psychotropic medicines. The global monitoring of country-level psychotropic medicine consumption trends can provide information on the extent of the availability of psychotropic medicines. The primary objective of this study was to investigate global trends in psychotropic medicines consumption from 2008 to 2019 across 65 countries and regions according to country income level and geographical region. Methods In this longitudinal trends study, we used pharmaceutical sales data from the IQVIA-Multinational Integrated Data Analysis System (IQVIA-MIDAS). We analysed monthly sales data of psychotropic medicines between Jan 1, 2008, and Dec 31, 2019. Total psychotropic medicine consumption included sales of antidepressants, antipsychotics, tranquilisers, sedatives or hypnotics, and mood stabilisers. Population estimates of each country or region (eight lower-middle-income countries, 19 upper-middle-income countries, and 38 high-income countries) were based on the UN World Population Prospects 2019 report. Average annual sales trends of psychotropic medicines, expressed as defined daily dose (DDD) per 1000 inhabitants per day, were estimated using a random-effects model adjusted for income level and region. Relative changes in the annual consumption of psychotropic medicines by income, expressed as DDD per 1000 inhabitants per day, were assessed as percentage change for each medicine class. Findings Psychotropic medicine sales increased from 28·54 DDD per 1000 inhabitants per day in 2008 to 34·77 DDD per 1000 inhabitants per day in 2019, corresponding to a 4·08% (95% CI 2·96-5·21) relative average increase annually. The absolute annual increase was greater in high-income countries (3·31 DDD per 1000 inhabitants per day, 95% CI 3·01-3·61) compared with upper-middle-income countries (1·94 DDD per 1000 inhabitants per day, 1·45-2·44) and low-middle-income countries (0·88 DDD per 1000 inhabitants per day, 0·62-1·13; p<0·0001). The relative average annual increase in psychotropic medicine sales from 2008 to 2019 was greater in upper-middle-income countries (7·88%, 95% CI 6·99-8·77) than in lower-middle-income countries (2·90%, 2·40-3·39) and high-income countries (1·02%, 0·80-1·24). In 2019, the regional consumption of psychotropic medicines varied greatly, with the highest sales of all psychotropic medicine classes reported in northern America (167·54 DDD per 1000 inhabitants per day) and lowest sales reported in Asia (5·59 DDD per 1000 inhabitants per day). 17 countries had very low consumption of psychotropic medicines in 2019, including high-income countries and countries with a high prevalence of mental disorders. Interpretation The consumption of psychotropic medicines has increased over a 12-year period, and although the absolute growth rate was highest in high-income countries, the relative growth is highest in middle-income countries and especially upper-middle-income countries. Disparities in psychotropic medicine consumption of countries can only partly be explained by geographical location and income. Greater efforts are needed to increase the availability of psychotropic medicines in countries with very low consumption, which is probably due to financial or cultural reasons as well as scarcity of trained health-care professionals to prescribe psychotropic medicines. Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data published in The Lancet indicate that the highest relative growth in psychopharmaceutical use between 2008 and 2019 took place in lower-middle-income countries across the Global South (Brauer et al. 2021).”
From Throwing therapy at the problem mental health and humanitarian intervention in Palabek refugee settlement, northern Uganda (2023) · cites this paper as Brauer et al. 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
No health without mental health
Prince, M. J., Patel, V., Saxena, S., Maj, M., Maselko, J., Phillips, M. R., & Rahman, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61238-0 · Cited by 4,028
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data
Boeckel, T. P. V., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B. T., Levin, S. A., & Laxminarayan, R. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70780-7 · Cited by 2,355
Undertreatment of people with major depressive disorder in 21 countries
Thornicroft, G., Chatterji, S., Evans-Lacko, S., Gruber, M., Sampson, N., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Andrade, L., Borges, G., et al. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.188078 · Cited by 1,121
Mental Illness Stigma, Help Seeking, and Public Health Programs
Henderson, C., Evans-Lacko, S., & Thornicroft, G. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301056 · Cited by 959
Mental Health Service Provision in Low- and Middle-Income Countries
Rathod, S., Pinninti, N., Irfan, M., Gorczynski, P., Rathod, P., Gega, L., & Naeem, F. (2017) · Health Services Insights · doi:10.1177/1178632917694350 · Cited by 866
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Alexander, G. C., Gallagher, S. A., Mascola, A. J., Moloney, R., & Stafford, R. S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2082 · Cited by 426
Cited by
Sorted by citations
Items 101–200 of 204
Beyond access to psychotropic medicines: treatment coverage amid COVID-19
Kola, L. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00431-4 · Cited by 2
Boland, M., Higgins, A., Beecher, C., Bracken, P. J., Burn, W., Cody, A., Framer, A., Gronlund, T. A., Horowitz, M. A., Huff, C., et al. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13649.1 · Cited by 3
de Gier, J. J., Bogaard, L., Siu, V. F., Todorov, B., Pinto, G. S., Viegas, R., Aldarij, N., van Dijk, L., & Borgsteede, S. D. (2024) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2024.100415 · Cited by 2
Mobile phone applications to support psychotropic tapering: a scoping review protocol
Boland, M., Higgins, A., Doherty, G. J., Sheaf, G., Framer, A., & Cadogan, C. A. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13501.2 · Cited by 1
Diving with psychotropic medication: review of the literature and clinical considerations
Praktijk Querido, H., Querido, A. L., Dutch Society of Diving and Hyperbaric Medicine, B., Ebbelaar, C. F., Wingelaar, T. T., & Dutch Society of Diving and Hyperbaric Medicine, B. (2023) · Diving and Hyperbaric Medicine Journal · doi:10.28920/dhm53.3.259-267 · Cited by 1
Psychotropic medications: a descriptive study of prescription trends in Tabriz, Iran, 2021–2022
Farahbakhsh, M., Fakhari, A., Azimian, A., Khameneh, A., Matinkia, M., & Aghajani, E. (2025) · BMC Psychiatry · doi:10.1186/s12888-024-06451-2 · Cited by 1
Liu, J., Li, Z., Deng, Z., Wang, Y., & Deng, F. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118587 · Cited by 1
Burger, R. L., Meffert, S. M., Ongeri, L., Wangia, J., Wambura, R., Ajore, P., Rota, G., Otieno, A. A., Obura, R. R., Muchembre, P., et al. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-017929 · Cited by 1
Hillen, J. B., Stanford, T., Ward, M., Duszynski, K. M., Tong, X., Li, S. X., Wong, I. C. K., & Pratt, N. L. (2025) · Value in Health Regional Issues · doi:10.1016/j.vhri.2025.101173 · Cited by 1
Self-citationWang, B., Liu, K. S. N., Mak, I. L., Choi, E. P. H., Lam, C. L. K., & Wan, E. Y. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70061 · Cited by 2
Feng, S., Zhu, L., Li, M., Xu, P., Xu, C., Lian, H., Gao, F., Cheng, X., & Xiang, X.-L. (2025) · Aquatic Toxicology · doi:10.1016/j.aquatox.2025.107637 · Cited by 1
Zhang, Y., Li, X., Wong, A. Y. S., Yan, V. K. C., Blais, J. E., Wong, J., Chan, E. W., & Leung, W. K. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107664 · Cited by 1
Self-citationSerotonin Application Decreases Fluoxetine-Induced Stress in Lemna minor and Spirodela polyrhiza
Wierzbicka, M., Michalczyk, D. J., & Piotrowicz-Cieślak, A. I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010002 · Cited by 1
Wang, B., Morris, S., Fry, H., Iona, A., Clarke, J., Lin, K., Pupko, I., Kartsonaki, C., Bennett, D. A., Chen, Y., et al. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100681 · Cited by 1
Adult ADHD in Cultural Ecosocial Niches: Exploring the Rise of Adult ADHD in Context
Ruse, J. N., & Rhodes, P. (2026) · Culture Medicine and Psychiatry · doi:10.1007/s11013-025-09958-9 · Cited by 2
Hernández, P. J. R., Perales, G. O., Esperón, C. S., Pedreira, P. A., Vico, L. A., Gómez, L. V., & Escalona, R. C. (2026) · Anales de Pediatría · doi:10.1016/j.anpedi.2026.504141 · Cited by 1
An Analysis of Psychiatric Workforce Distribution in the Philippines
Anlacan, J. P., Anlacan, V. M. M., de Guzman, H. J. D., Anlacan, B. M., & Jamora, R. D. G. (2026) · Healthcare · doi:10.3390/healthcare14081064 · Cited by 1
Liu, Y., Li, M., Yu, J., Yu, F., Lu, L., Chen, J., & Guo, R. (2026) · Aquatic Toxicology · doi:10.1016/j.aquatox.2026.107885 · Cited by 1
Simal, I., Vanneste, O., Capiau, A., Petrović, M., Mariman, A., Boussery, K., & Somers, A. (2026) · Acta Clinica Belgica · doi:10.1080/17843286.2026.2711891 · Cited by 1
Kodalkar, D., Kulkarni, A. S., Shrivastav, B., & Tare, H. L. (2022) · International Journal of Pharmaceutical Quality Assurance · doi:10.25258/ijpqa.13.4.11 · Cited by 1
Aproximación 4E/MoBI en práctica: Implicancias para la psicología y la psiquiatría
Boehm, S., Grasso‐Cladera, A., Reardon, E., Costa‐Cordella, S., & Parada, F. J. (2024) · Andamios · doi:10.29092/uacm.v21i54.1062
Rodrigues, A., Kohli, N., Watson, C., & Boynton, K. (2025) · International Journal of Mental Health Nursing · doi:10.1111/inm.70068 · Cited by 1
Koch, T., von Peter, S., Weinmann, S., & Ruiz‐Pérez, G. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116685 · Cited by 1
Purić, D., Petrović, M., Živanović, M., Lukić, P., Zupan, Z., Branković, M., Ninković, M., Lazarević, L. B., Stanković, S., & Žeželj, I. L. (2022) · Research Square · doi:10.21203/rs.3.rs-2222682/v1 · Cited by 1
Comparison of drug utilization across countries
YaredSanta‐Ana‐Téllez, & Elseviers, M. M. (2024) · doi:10.1002/9781119911685.ch24 · Cited by 1
Torre, C. (2023) · London School of Economics and Political Science (LSE) · doi:10.21953/lse.00004557
Boland, M. (2022) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2022.03.001
Anesthetic Concerns in Psychiatric Disease
Martinez-Baladejo, M. T., Liongson, F. A. Z., Wong, D., Spoleti, C., Suyumov, D., Menghani, S. V., McCarthy, C., Divito, A. J., Daniel, S. V., Salpekar, S., et al. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110173 · Cited by 1
Dispensing of Psychotropic Medications in Australia between 2013 and 2022Preprint
Almeida, O. P., Etherton‐Beer, C., Sanfilippo, F. M., Preen, D. B., & Page, A. T. (2023) · doi:10.22541/au.168963256.60688096/v1
Farmakológiai biopolitikák (1. rész) : A lélek vegyészete
Básthy, Á., & Lengyel, Z. (2023) · Replika · doi:10.32564/129.1
Martinez, J. A., & Martinez-Gongora, K. (2023) · Advances in higher education and professional development book series · doi:10.4018/979-8-3693-0708-3.ch009
Λέκκα, Β. (2024) · Επιθεώρηση Κοινωνικών Ερευνών · doi:10.12681/grsr.36708
Jovanović, Ž., Pešut, S., & Miletić, B. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1339246
Psikofarmakoloji: Psikiyatri Hemşireleri Neleri, Neden Bilmeli?
Murat, M., & Küçük, L. (2024) · Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi · doi:10.31125/hunhemsire.1169736
Research Letter: Dispensing of psychotropic medications in Australia between 2013 and 2022
Almeida, O. P., Etherton‐Beer, C., Sanfilippo, F. M., Preen, D. B., & Page, A. T. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241270918
Analytical studies in drug utilization research
Samuelsen, P., Wettermark, B., & Elseviers, M. M. (2024) · doi:10.1002/9781119911685.ch6
Fernandes, P. D. J., Scorsolini‐Comin, F., Belchior, D. V., de Almeida, J. C. P., de Oliveira, J. L., & de Souza, J. (2024) · Revista gaúcha de enfermagem · doi:10.1590/1983-1447.2024.20230197.en
Fernandes, P. D. J., Scorsolini‐Comin, F., Belchior, D. V., de Almeida, J. C. P., de Oliveira, J. L., & de Souza, J. (2024) · Revista gaúcha de enfermagem · doi:10.1590/1983-1447.2024.20230197.pt
Psychopharmacological approaches to somatization with a focus on cross-cultural differences
Shoib, S., Saeed, F., Swed, S., & Ransing, R. S. (2025) · doi:10.1093/med/9780192858290.003.0020
Huang, C., Yu, Y., Wei, Y., Yan, V. K. C., Lee, K. J., Leung, S. M., Lai, F. T. T., Chai, Y., Brauer, R., Castle, D. J., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5134442
Self-citationDie Gesellschaft der verletzten Seelen und die Wissensordnung der Psychiatrie
von Kardorff, E., Harbusch, M., & Robin, D. (2025) · Springer eBooks · doi:10.1007/978-3-658-47031-9_2
López, I. F., Bermúdez, E. G., Martín, F. A., Morente, A. G.-D., Fernández, M. D. M., Cañete, Y. S., & Bermúdez‐Tamayo, C. (2025) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2025.03.063 · Cited by 1
Karlsen, J. H., Jacobsen, P. A., Brath, M. S. G., & Weinreich, U. M. (2025) · European Clinical Respiratory Journal · doi:10.1080/20018525.2025.2484080
Oliva, A., Moreno, V., Sapino, M., Dévora, S., & Abdala, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1511936 · Cited by 1
Zhao, X., Zhang, L., Kramer, L., Wang, B., Guan, M., & Ma, Q. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2529772
Gurzó, K., Oksuzyan, A., & Modin, B. E. (2026) · European Journal of Epidemiology · doi:10.1007/s10654-026-01425-y
Boland, M., Higgins, A., Kwak, S., & Cadogan, C. A. (2025) · Health Expectations · doi:10.1111/hex.70384
Turbulent-like Dynamics Predict Treatment Outcome in Major Depressive DisorderPreprint
Ruhé, H. G., Poirot, M. G., Perl, Y. S., Caan, M. W. A., Marquering, H. A., Deco, G., Kringelbach, M. L., & Reneman, L. (2025) · Research Square · doi:10.21203/rs.3.rs-7208894/v1
Cuesta‐Zigorraga, A., & Rodríguez, C. L. H. (2025) · Health Expectations · doi:10.1111/hex.70361
van den Buuse, M., Wilson, K.-E., Payet, J. M., & Hale, M. W. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.032
Safety of Antidepressants: Analysis of the Russian Database of Spontaneous Reports
Gomon, Y. М., Анатольевна, Л. В., Колбин, А. С., Витальевич, Г. К., Незнанов, Н. Г., & Sultanova, F. М. (2025) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2025-521
Benning, K., van Dijk, L., de Gier, J. J., & Borgsteede, S. D. (2025) · Pharmacy · doi:10.3390/pharmacy13050146
Portela, L. A., Gandara, B. F., Melo, M. S., de Araújo, A. E. T., Florêncio, P. C. M., Esteves, M. I. P. D. L., Rêgo, F. M. P. D. S., & Rêgo, G. (2025) · Research Square · doi:10.21203/rs.3.rs-7110198/v1
Chertkova, O., & Hoshtynar, K. (2025) · Ukrainian Scientific Medical Youth Journal · doi:10.32345/usmyj.3(157).2025.155-160
Brodeur, S., Corbeil, O., Béchard, L., Huot‐Lavoie, M., Desmeules, C., Oliver, D., Micheli, A. D., Osimo, E. F., Upthegrove, R., Khandaker, G. M., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf174
Zhang, C., Dong, H., Zhao, X., Fang, C., Tong, Y., & Niu, J. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112038
Yao, H., Peng, Z., Huang, Y., Xiao, S., & Wu, R. (2025) · BMC Medicine · doi:10.1186/s12916-025-04420-4
Yin, J., Song, X., Wang, C., Lin, X., & Miao, M. (2023) · Figshare · doi:10.6084/m9.figshare.24633276
Twenty‐Five Percent of Patients Undergoing Knee Arthroscopy Use Psychotropic Medications
Ramsey, Z., Ierulli, V. K., Gerard, N. O., Saraf, S. M., Heard, W., & Mulcahey, M. K. (2025) · Arthroscopy Sports Medicine and Rehabilitation · doi:10.1016/j.asmr.2025.101251
Tan, J. E. T., Ayran, C. M. G., Gloria, M. A. J., Mendoza, A. E. G., Tronco, J. L. D., Mercado, J. M. M., & Capule, F. R. (2025) · Research in Clinical Pharmacy · doi:10.59931/rcp.25.0015
Sun, J., Fang, H.-A., Zheng, Y., Pereira-LIma, K., Tong, S., Zhang, S.-N., Wang, L.-Y., Fan, S.-Y., Xia, Y., Zhang, Y.-N., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8729203/v1
Boulahia, M. (2026) · medRxiv · doi:10.64898/2026.01.15.26344188 · Cited by 1
Psychotropic medication and the fetal brain
Gale‐Grant, O., & Arichi, T. (2026) · The Journal of Physiology · doi:10.1113/jp289602
All Things Being Equal, Global Antiseizure Medications Consumption Remains Unequal
Karakis, I. (2026) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597261423666
Shepherd, R. A., Stacey, D., Janetzki, J., Clark, S., Hyppönen, E., & Suppiah, V. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.02.014
Psychotropic medications in Pediatric practice
Hernández, P. J. R., Perales, G. O., Esperón, C. S., Pedreira, P. A., Vico, L. A., Gómez, L. V., & Escalona, R. C. (2026) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2026.504141
Martínez-Mendia, X., Amaia Bacigalupe, H., & Moreno‐Llamas, A. (2026) · European Journal of Public Health · doi:10.1093/eurpub/ckag034
Pei, Z., Ong, S. K., Yi, S., Hon, C., & Xu, M. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108586
Effects of Long-Term Consumption of Anxiolytics, Antidepressants, and Hypnotics on Working Memory
Cansino, S., Torres-Trejo, F., Estrada-Manilla, C., & RUIZ-VELASCO, S. (2026) · Experimental Aging Research · doi:10.1080/0361073x.2026.2652815
Guo, W., Jin, B., Pang, L., Liu, Y., Liu, D., 董自梅, & Chen, G. (2026) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2026.110548
Spatiotemporal analysis of psychoactive drug consumption in Brazil during the COVID-19 pandemic
de Freitas, E. L., Erbisti, R. S., Grinberg-Weller, B., Pinto, D. C. C., & Miranda, E. S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343552
Gahr, M., Mischke, K., Paulzen, M., & Diefenbach, L. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2866-8844
Commercial-Friendly Mental Health Narratives Undermine Community Mental Health: A Call for Action
Cosgrove, L., Pelton-Flavin, K., McCarty, S. M., Baez, A., Abi‐Jaoude, E., Cooper, C., & Shaughnessy, A. S. (2026) · Community Mental Health Journal · doi:10.1007/s10597-026-01659-w
Physical inactivity, a risk factor for mental disorders in Spanish youth: a cross-sectional study
Pastor-Cisneros, R., Pereira-Payo, D., Denche-Zamorano, Á. M., Mendoza-Muñoz, M., Calzada-Rodríguez, J. I., & Franco-García, J. M. (2026) · Journal of Public Health · doi:10.1007/s10389-026-02785-1
Wang, W., Xie, T., Chen, G., Li, L., Zhang, H., Sun, T., Cui, B., & Cai, Z. (2026) · Water Research · doi:10.1016/j.watres.2026.126278
Khan, M. U., & Hasan, S. S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0349877
Koch, T., Peter, S., Weinmann, S., & Ruiz‐Pérez, G. (2026) · Neuropsychiatrie · doi:10.1007/s40211-026-00583-5
The “Mental Health Crisis,” a Political Issue
Bernheim, E. (2026) · The politics of mental health and illness · doi:10.1007/978-3-032-16186-4_2
van der Meer, M. Z., Rasmussen, B. S., Nedahl, M., & Nielsen, M. K. K. (2026) · Journal of Analytical Toxicology · doi:10.1093/jat/bkag065
LPS‑induced impairment of neuroregeneration is alleviated by fluoxetine in Dugesia japonica
Yuan, Z., Huang, J., Chen, Q., Sun, J., Cao, R., Shi, H., Li, R., & Zhang, J. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116385
Asir, B., Al‐Soleiti, M., & Singh, B. (2026) · Drugs & Aging · doi:10.1007/s40266-026-01315-8 · Cited by 1
Crisis, adolescence, and mental health: considerations from the Theory of Subjectivity
Cobucci, B. R. B., & Goulart, D. M. (2026) · Estudos de Psicologia (Campinas) · doi:10.1590/1982-0275202643e14598
Twenty-Year Trends in Antipsychotic Utilization in Serbia: A Nationwide Drug Utilization Study
Pavlović, Z., Stevanovic, M., Milić, M., Filimonovic, J. S., Matejić, B., Bogdanović, M., Vukajlovic, I., Krstić, A., Milenovic, M. S., & Dunjić-Kostić, B. (2026) · Pharmaceuticals · doi:10.3390/ph19071128
Delgado, D., Lertxundi, U., Brizuela, L., Orive, G., & Sánchez, M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104749
Şanko, V., Okan, M., Külah, H., & Tekin, H. C. (2026) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2026.120470
Martyniuk, O. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1832027
Ferreira, J. V. D. S., Vanoli, J., Müller, T., & Vicedo-Cabrera, A. M. (2026) · Research Square · doi:10.21203/rs.3.rs-10436313/v1
Mehmedović, A., Milojevic, T., Binić, I., Brkić, M. Z., Buzejić, J., Cosgrove, L., Čorić, J., Dabetic, M., Đilas, B. Ž., Đurović, M., et al. (2026) · Medical Decision Making · doi:10.1177/0272989x261464576
Kvaløy, S. M., Synnes, O., & Austad, A. (2026) · Religions · doi:10.3390/rel17090993
Kassandros, K., Samakouri, M. A., Παναγοπούλου, Μ., Constantinidis, T., & Kontogiorgis, C. (2026) · Frontiers in Drug Safety and Regulation · doi:10.3389/fdsfr.2026.1900494
Sun, Y., Lu, M., Zhang, Y., Xu, J., Chen, F., Hu, J., & Yuan, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1926315
Craig, A. M., Clemens, K. J., & Leigh, S. (2026) · Clinical Science · doi:10.1042/cs20250049
Risk of Antidepressant-Induced Tardive Dyskinesia: A Scoping Review of Evidence and High-Risk Agents
Siopa, C., Correia, L., Estibeiro, M. J., Chaves, I., & Pestana, P. C. (2026) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-026-00388-x
Gawłowska, K., Nowakowska, K., Makówka, J., Bajurny, W., Góral, M. P., Bocheńska, A., Kopecki, S. D., Grodzińska, W., & Chłopaś-Konowałek, A. (2026) · Molecules · doi:10.3390/molecules31173130
Risk factors for idiopathic granulomatous mastitis: scoping review
Castelhano, R., Argus, L., Ahari, D., Johri, G., MacInnes, E., Shah, S., Darlow, C. A., Sharma, V., Shukla, R. R., Lyburn, I., et al. (2026) · BJS Open · doi:10.1093/bjsopen/zrag137
Zavaleta‐Monestel, E., Herrera-Jiménez, L. G., Arguedas‐Chacón, S., Castro-Gamboa, J. A., Cruz-Mora, K., Mora-Jiménez, J., & Millán-González, R. (2026) · Psychoactives · doi:10.3390/psychoactives5040027
Psychotropic drugs in drinking water? A scoping review of evidence on diazepam and fluoxetine
Teixeira, P. A. F., Pereira, B. A., Carneiro, R. D. S., de Assis, L. J. M., Leal, M. L. S., & Marcon, M. (2026) · Environmental Science and Pollution Research · doi:10.1007/s11356-026-38296-5
Salvador-Carrillo, J., Figueiredo-Modesto, A. C., Lopes, L. C., Flores-Flores, C., Pinto, J., & Huarcaya-Victoria, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1892034
Bilal, M., Kumari, M., Farooq, S. Z., Sajjad, F., Ullah, M. S., Akif, M., Iftikhar, S., Saddique, M. N., & Nazari, M. J. (2026) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.70427
Metadata
- Authors
- Brauer, R., Alfageh, B., Blais, J. E., Chan, E. W., Chui, C. S. L., Hayes, J. F., Man, K. K. C., Lau, W. C. Y., Yan, V. K. C., Beykloo, M. Y., Wang, Z., Wei, L., & Wong, I. C. K.
- Affiliations
- UCL School of Pharmacy (GB)
- King Saud University (SA)
- University of Hong Kong (HK)
- Laboratory of Data Discovery for Health (HK)
- University College London (GB)
- Corresponding author
- Wong, Ian C K
- ORCID
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 8
- Issue
- 12
- Pages
- 1071-1082
- ISSN
- 2215-0366 (ISSN-L)
- PMC
- PMC9766760
- OpenAlex
- W3215716001
- Cited by
- 203
- References
- 39
- Citations by year
- 2026: 55 · 2025: 68 · 2024: 30 · 2023: 31 · 2022: 17 · 2021: 2
- FWCI
- 19.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- National Institute for Health Research
- Amgen
- European Commission
- Bristol-Myers Squibb
- National Health and Medical Research Council
- Pfizer
- National Natural Science Foundation of China
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Hospital Authority
- Novartis
- Food and Health Bureau
- Takeda Pharmaceutical Company
- Innovation and Technology Commission - Hong Kong
- Janssen Pharmaceuticals
- Wellcome Trust (211085/Z/18/Z)
- Research Grants Council, University Grants Committee
- GlaxoSmithKline
- University of Hong Kong
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
- Keywords
- psychotropic drugs, antidepressants, antipsychotic drugs, sedative-hypnotic drugs, mood stabilizers, defined daily doses, drug sales, mental health indicators, country income level, global trends, mental health policy, access to mental health care, mental health funding
- MeSH terms
- Mental Disorders, Drug Utilization, Health Services Accessibility, Humans, Longitudinal Studies, Psychotropic Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
